Programmed death receptor-1 inhibitor
PreclinicalSmall molecule
Programmed death receptor-1 inhibitor is one of 10 small molecule programs targeting Malignant Pleural Mesothelioma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Malignant Pleural Mesothelioma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Photofrin
PPinnacle Biologics Inc.
Approved
Alimta
SShawn Eagle
Phase 3
Tecentriq
RochePhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Lenvima
EisaiPhase 2
OT-101
OOncotelic Inc.
Phase 2
Programmed death receptor-1 inhibitor
TTianjin Medical University Second Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details